Fulgent Genetics (NASDAQ:FLGT) Issues Quarterly Earnings Results

Fulgent Genetics (NASDAQ:FLGT) issued its quarterly earnings results on Friday. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.14, FiscalAI reports. The firm had revenue of $83.34 million during the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%. Fulgent Genetics updated its FY 2026 guidance to -1.450–1.450 EPS.

Here are the key takeaways from Fulgent Genetics’ conference call:

• The company’s largest customer is moving substantial testing in‑house, cutting expected 2026 revenue from that customer from $70.8M in 2025 to about $11.8M, creating a front‑loaded revenue and margin headwind in H1 2026.
• Fulgent agreed to acquire Bako Diagnostics and StrataDx for roughly $55.5–$56M, which management expects to add about $50–$55M of revenue, expand the anatomic pathology salesforce, and materially reduce customer concentration if the deals close in March 2026.
• Management emphasized technology gains — an in‑house digital pathology/image management platform (EasyoPath) and multiple AI modules are now deployed, which they say is improving throughput, quality and long‑term operating leverage.
• Therapeutic pipeline progress: FID‑007 completed Phase 2 enrollment (46 patients) with encouraging early efficacy/safety and is targeting an FDA interaction in mid‑2026 and potential Phase 3 start in 2027, while FID‑022 is advancing through dose escalation.
• Financial picture is mixed — 2025 revenue grew 14% to $322.7M and beat non‑GAAP EPS guidance, but Q4 GAAP loss widened to $23.4M, adjusted EBITDA turned negative, and 2026 guidance forecasts ~$350M revenue with a non‑GAAP EPS loss of $1.45 and wider operating losses due to acquisition, R&D and sales investments.

Fulgent Genetics Stock Down 38.1%

Shares of NASDAQ:FLGT traded down $9.43 during midday trading on Friday, hitting $15.33. 2,610,665 shares of the stock traded hands, compared to its average volume of 222,404. The business’s 50 day moving average is $25.66 and its two-hundred day moving average is $24.83. The stock has a market capitalization of $473.85 million, a PE ratio of -11.03 and a beta of 0.86. Fulgent Genetics has a one year low of $14.57 and a one year high of $31.04.

Insider Activity

In related news, COO Jian Xie sold 1,140 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total transaction of $32,296.20. Following the transaction, the chief operating officer owned 336,749 shares in the company, valued at $9,540,099.17. The trade was a 0.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Hanlin Gao sold 1,075 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total value of $30,454.75. Following the transaction, the insider directly owned 952,890 shares of the company’s stock, valued at $26,995,373.70. The trade was a 0.11% decrease in their position. The disclosure for this sale is available in the SEC filing. 31.76% of the stock is owned by company insiders.

Institutional Trading of Fulgent Genetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new position in Fulgent Genetics during the fourth quarter valued at $35,000. Raymond James Financial Inc. bought a new position in shares of Fulgent Genetics during the second quarter valued at $49,000. Quantbot Technologies LP purchased a new position in shares of Fulgent Genetics in the 3rd quarter worth about $61,000. Los Angeles Capital Management LLC purchased a new position in shares of Fulgent Genetics in the 4th quarter worth about $218,000. Finally, Advisors Asset Management Inc. boosted its stake in Fulgent Genetics by 2,205.7% in the 4th quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after purchasing an additional 8,117 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on FLGT shares. Wall Street Zen cut shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Raymond James Financial reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Fulgent Genetics in a research note on Friday, November 14th. Piper Sandler increased their target price on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Finally, Zacks Research lowered shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.00.

More Fulgent Genetics News

Here are the key news stories impacting Fulgent Genetics this week:

• Positive Sentiment: Q4 EPS beat consensus, reporting $0.16 vs. estimates near $0.02–$0.03 — a clear near‑term earnings upside that shows some operational strength. Zacks: Q4 Earnings Top Estimates
• Positive Sentiment: Company issued FY‑2026 revenue guidance of $350M, which is roughly above/near consensus (~$343.6M) and signals revenue growth expectations as the business mix shifts. Seeking Alpha: Forecasts $350M 2026 Revenue
• Neutral Sentiment: Management highlighted acquisitions (Bako, StrataDx) that are reshaping the customer mix — these can drive revenue scale over time but bring integration expense and timing uncertainty. Seeking Alpha: Acquisitions Reshape Customer Mix
• Neutral Sentiment: Q4 revenue was $83.34M, a modest miss vs. analyst expectations (~$85M), and the company reported negative net margin and ROE — mixed operating metrics that temper the EPS beat. MarketBeat: Q4 Results & Transcript
• Negative Sentiment: The principal negative: FY‑2026 EPS guidance of about -$1.45 is far below the consensus estimate (~- $0.59), signaling a much larger expected loss than analysts anticipated — the main driver of the sharp selloff. Seeking Alpha: Guidance Details
• Negative Sentiment: Market commentary and coverage note the guidance shock and integration/expense risk as reasons for the heavy share decline; coverage pieces summarize why the stock pulled back sharply after the release. AAII: Why FLGT Stock Is Down

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.